Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 202
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2018miR-375miRNAHumanDownregulated in Cancer Diagnostic and PrognosticLiver cancer v/s Normal p < 0.01Tissue28781668
2019miR-221miRNAHumanUpregulated in Cancer Diagnostic and PrognosticLiver cancer v/s Normal p < 0.01Tissue28781668
2025miR-34a-5pmiRNASprague- Dawley rats Upregulated in TAA-induced hepatocarcinogenesis (with Log fold change more than 1.5 to 4.7) Potential Diagnostic and Prognostic *Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC p < 0.05Tissue28596526
2026miR-455-3pmiRNASprague- Dawley rats Downregulated in TAA-induced hepatocarcinogenesis Potential Diagnostic and Prognostic *Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC p < 0.05Tissue28596526
2028EMP1-008LncRNAHumanDownregulated in ICC (with log fold change of more than 2) Diagnostic and PrognosticICC v/s Normal; significantly downregulated in ICC with tumor metastasis p < 0.05Tissue28401021
2029ATF3-008LncRNAHumanDownregulated in ICC (with log fold change of more than 2) Diagnostic and PrognosticICC v/s Normal; significantly downregulated in ICC with tumor metastasis p < 0.05Tissue28401021
2030RCOR3-013LncRNAHumanDownregulated in ICC (with log fold change of more than 2) Diagnostic and PrognosticICC v/s Normal; significantly downregulated in ICC with tumor metastasis p < 0.05Tissue28401021
2032miR-9-3RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2033miR-10bRNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2034miR-31RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2035miR-519cRNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2036miR-522RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2037miR-3660RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2038miR-4784RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2039miR-6883RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2040Promoter methylation of HCCS1RNAsHumanNA Diagnostic and PrognosticHCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage p < 0.001Serum28189396
2041AFPProtein HumanNA Diagnostic and PrognosticHCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage p < 0.001Serum28189396
2042AFP, Promoter methylation of HCCS1Protein and RNAHumanNA Diagnostic and PrognosticHCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage p < 0.05Serum28189396
2044lncBRMLncRNAHumanUpregulated in HCC tumours and liver CSCs Diagnostic and PrognosticLiver CSCs (Cancer stem cells) and early and advanced HCC tumours p < 0.001Tissue27905400
2053CFL1ProteinHuman cell lines and Mice Upregulated in HBV-HCC Diagnostic and PrognosticHBV-HCC vs normal p < 0.05Tissue27708241
2054ADFPProteinHuman cell lines and Mice Upregulated in HBV-associated HCC Diagnostic and PrognosticHBV-HCC vs normal p < 0.05Tissue27708241
2055TRIM32ProteinHumanUpregulated in HCC tumor tissues and HCC cell lines. Diagnostic and PrognosticHCC v/s Normal; significant predictor for the overall survival time of HCC patients and positively correlated with histological grade, tumor sizes of patients p < 0.05Tissue27573002
2058HIF1AProteinHumanUpregulated in at both an mRNA and protein level in patients with PLC Diagnostic and PrognosticCancer v/s Normal; predict survival of patients p < 0.05Tissue27173353
2059VEGFProteinHumanUpregulated in at both an mRNA and protein level in patients with PLC Diagnostic and PrognosticCancer v/s Normal; predict survival of patients p < 0.05Tissue27173353
2088Aspartate aminotransferase to white blood cell count ratio (AWR)OthersHumanAWR > 5.2 was an adverse predictor of DFS and OS in HCC after hepatectomy PrognosticHCC patients with AWR >5.2 v/s HCC patients with AWR <5.2; predict survival of patients p < 0.01Blood27057915
2092DLC1RNAsHumanDownregulated in HCC PrognosticCancer v/s Normal; predict survival of patients p < 0.05Tissue26846339
2102CPERNAsHumanCPE expression level was also significantly correlated with the tumor recurrence for both stage i.e. Stage-I and Stage-II PrognosticRecurrence between stage-I v/s stage-II p < 0.01Tissue26803519
2107Combination of S100A9 and GRNOthersHumanDownregulated in HCC patients Diagnostic and PrognosticNormal vs HCC p < 0.001Urine26675302
2109DHCR24 Auto-antibodyProteinHumanUpregulated in CHC (Chronic Hepatitis C) v/s healthy PrognosticNormal vs Chronic heaptitis (CHV) p < 0.0001Serum26288822
2110DHCR24 Auto-antibodyProteinHumanDHCR24 was up-regulated in HCV-positive, but not HBV-positive tissues or HBV-negative, HCV-negative HCC PrognosticHCC vs Chronic heaptitis (CHV)/healthy/Liver cirrhosis p < 0.0001Serum26288822
2116miR-128-2miRNAHumanUpregulated in HCC tissues PrognosticHCC v/s Normal, predict survival of patients p < 0.01Serum25642945
2118HNF4A, RelAmiRNAHumanupregulated in hepatoma cells PrognosticL-HNF4α group v/s hig-HNF4α group; associated with survival of patients p < 0.05Tissue24752868
2132CYP3A4ProteinHumanUpregulated in in hepatitis B virus-associated liver cirrhosis and stage I hepatocellular carcinoma, PrognosticHCC vs adjacent non-tumor and stageII v/s stage-III; predict early stage p < 0.05Tissue and Cells 23891548
2133miR-1miRNAHumanIncreasead concentration showed longer OS in HCC PrognosticHCC v/s Liver Cirrhosis; predict survival of patients p < 0.01Serum23810247
2134ENO1ProteinHumanUpregulated in patients with precirrhotic stage of liver fibrosis than that in patients with cirrhosis/liver cancer/healthy individuals. PrognosticLiver fibrosis v/s cirrhosis/liver cancer/normal; predict early stage of disease p < 0.01Serum23458688
2135XPO4ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2136TGFβ1ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2137elF5A2ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2138ANGPTL4ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2160miR-515-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2161miR-518a-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2162miR-520fmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2163miR-525-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2167CORO1CProteinHumanUpregulated in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis and higher coronin-1C expression had more advanced stage in patients PrognosticAgressive or advanced-stage HCC v/s less-aggressive HCC; predict metastatic stage p < 0.05Tissue and Cells 20181269
2178miR-122miRNAHumanvariable expression between different hepatoma cell lines: PLC/PRF/5, Huh-1, and Hep40 exhibited very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (e.g. SNU387, and SNU398) ; in HCC patients miR-122 was specifically repressed in Diagnostic and PrognosticNormal vs HCC; associated with survival, tumor size and differentiation status p < 0.001Tissue and Cells 19617899
2179lamin B1ProteinHumanUpregulated in liver cancer patients Diagnostic and PrognosticNormal vs HCC; significantly associated with the increased number of tumor nodules , the size of tumors, and tumor stage p < 0.01Plasma19522540
2199MTHFRRNAsHumanMTHFR polymorphism was associated with HCC occurrence PrognosticNormal vs HCC; predict recurrence in patients p < 0.05Tissue29185200
2207NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index)Neutrophils and lyphocytes (Others)HumanNLR and SII in patients associated with more advanced stages of HCC PrognosticNormal vs HCC; associated with TNM stage, PST and survival of patients p < 0.05Blood29123264
2208SULT1A3/4ProteinHumanUpregulated in HCC PrognosticHCC v/s Normal; associated with metastatsis of patients p < 0.01Tissue29025375
2219AFP, GGT, ALT, ASTProteinMale Sprague-Dawley ratsDownregulated Potential Prognostic *HCC v/s Normal/treated with AEA; associated with progression p < 0.0001Serum28900384

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top